drugset
drugset / Trial / NCT03940053

Prevention of Cancer Development and Progression

NCT03940053 ↗

Phase 3 Unknown 300 enrolled Zujiang YU
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the efficacy and safety of arginine in preventing cancer development

Timeline

Start
2019-05-10
Primary completion
2024-08-10
Completion
2025-05-10

Drugs

EvaluationDrugModalityDoseRoute
Subject L-arginine Small molecule 5 g Intravenous

Indications

cancer